S. Lorenzotti

发表

A survey of methicillin-resistant Staphylococcus aureus control strategies in Italy

A. Goglio, A. Pan, L. Signorini, 2013, Infection.

Community-acquired Methicillin-Resistant Staphylococcus aureus ST398 Infection, Italy

A. Pantosti, M. Boldini, A. Pan, 2009, Emerging infectious diseases.

Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery.

S. Giulini, S. Bonardelli, P. Viale, 2006, International journal of antimicrobial agents.

Adherence to hand hygiene in an Italian long-term care facility.

G. Carosi, A. Pan, L. Signorini, 2008, American journal of infection control.

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function

S. Di Giambenedetto, C. Torti, E. Quiros-Roldan, 2016, The open AIDS journal.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Low Rates of Nasal Colonization With Methicillin-Resistant Staphylococcus aureus Among Staff Members of an Italian Hospital

A. Pan, L. Signorini, S. Lorenzotti, 2006, Infection Control & Hospital Epidemiology.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

S. Leone, S. Lo Caputo, F. Mazzotta, 2015, International journal of epidemiology.

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections

G. Dolci, M. Meschiari, C. Mussini, 2021, JAC-antimicrobial resistance.

Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection.

A. Pan, S. Lorenzotti, A. Zoncada, 2008, Recent patents on anti-infective drug discovery.

Epidemiological and Clinical Characterization of Superinfections in Critically Ill Coronavirus Disease 2019 Patients

J. Marshall, N. Latronico, S. Calza, 2021, Critical care explorations.

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

M. Metra, N. Latronico, D. Rizzoni, 2020, Autoimmunity Reviews.

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

M. Prosperi, S. Di Giambenedetto, C. Torti, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol)

Federica Re, Domenico Russo, L. Signorini, 2022, Frontiers in Oncology.

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

F. Montagnini, M. Giacomini, G. Innocenti, 2020, Journal of Translational Medicine.

Hand Hygiene and Glove Use Behavior in an Italian Hospital

K. Posfay-Barbe, A. Pan, P. Mondello, 2007, Infection Control & Hospital Epidemiology.

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

S. Giambenedetto, S. Costarelli, S. Lorenzotti, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.